A profile about the people, projects and experiences behind their work. Discover their career, contributions and connections.
Backed byDetails being loaded
Cosigned byDetails being loaded
Team on CosignDetails being loaded
Team
Team
5
Profile nameProfile nameProfile name
Team
5
Profile nameProfile nameProfile name
Cosigns Received
Cosigner name
A thoughtful collaborator who builds great products and supports the people around them.
Profile name
Cosigner name
A thoughtful collaborator who builds great products and supports the people around them.
Profile name
Loading organization
Organization name
A profile about the people, projects and experiences behind their work. Discover their career, contributions and connections.
Backed byDetails being loaded
Cosigned byDetails being loaded
Team on CosignDetails being loaded
Team
Team
5
Profile nameProfile nameProfile name
Team
5
Profile nameProfile nameProfile name
Cosigns Received
Cosigner name
A thoughtful collaborator who builds great products and supports the people around them.
Profile name
Cosigner name
A thoughtful collaborator who builds great products and supports the people around them.
Profile name
Loading organization
Organization name
A profile about the people, projects and experiences behind their work. Discover their career, contributions and connections.
Backed byDetails being loaded
Cosigned byDetails being loaded
Team on CosignDetails being loaded
Team
Team
5
Profile nameProfile nameProfile name
Team
5
Profile nameProfile nameProfile name
Cosigns Received
Cosigner name
A thoughtful collaborator who builds great products and supports the people around them.
Profile name
Cosigner name
A thoughtful collaborator who builds great products and supports the people around them.
Profile name
Genexine, Inc.
Genexine, Inc. is a publicly traded, clinical-stage biotechnology company focused on developing and commercializing immunotherapeutics and next-generation . Its primary technology platforms are Therapeutic DNA vaccine and hyFc® long-acting technology and bioPROTAC. The company has multiple products in clinical development including several undergoing Phase 3 registrational trials.
The company's proprietary pipeline includes GX-188E (tirvalimogene teraplasmid) for head and neck cancer and cervical cancer, GX-I7 (efineptakin alfa) for multiple solid cancers and ARS, GX-H9 (eftansomatropin alfa) for Pediatric Growth Hormone Deficiency and GX-E4 for CKD-induced anemia, among others.
in 2024, Genexine has completed a merger with 'EPD biotherapeutics' and acquired future focusing new modality 'bioPROTAC' platform technology which now in pre-clinical development focusing on oncology.
The company has established multiple partnerships with global companies in order to expedite product development and commercialization and create significant value.
Genexine is listed on the Korean exchange (KOSDAQ: 095700) and is headquartered in Seoul, Korea. Genexine is committed to the well-being
Backed by
Loading investors
Founders
Loading founders
Cosigned by
Loading cosigns
Featured roles
Loading featured roles
Team
Loading company relationships
Team
5
Profile nameProfile nameProfile name
Team
5
Profile nameProfile nameProfile name
Loading company cosigns
Cosigner name
A thoughtful collaborator who builds great products and supports the people around them.
Profile name
Cosigner name
A thoughtful collaborator who builds great products and supports the people around them.